Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults

Expert Opinion on Emerging Drugs

Volumn 11, Issue 2, 2006, Pages 217-230

  Fortin, Claude ^a   Joly, Véronique ^b   Yeni, Patrick ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b BICHAT HOSPITAL   (France)

Author keywords

Antiretroviral drug; Human immunodeficiency virus; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 3' FLUOROTHYMIDINE; ABACAVIR; AMDOXOVIR; ANTIRETROVIRUS AGENT; BCH 10618; BILR 355; CALANOLIDE A; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GW 695634; LAMIVUDINE; NEVIRAPINE; PSI 5004; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ERUCTATION; FATIGUE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LIPODYSTROPHY; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NAUSEA; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATIENT COMPLIANCE; RASH; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VASCULITIS; VIRUS REPLICATION;

ADULT; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33646576568     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.2.217     Document Type: Review

References (93)

1. REEVES JD, PIEFER AJ: Emerging drug targets for antiretroviral therapy. Drugs (2005) 65:1747-1766.
2. DE CLERCQ E: Antiviral drugs in current clinical use. J. Clin. Vir. (2004) 30:115-133.
3. PALELLE FJ Jr, DELAMEY KM, MORGAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338:853-860.
4. COOPER DA, LANGE JM: Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discoveryand development. Lancet Infect. Dis. (2004) 4:426-436.
5. YENI PG, HAMMER SM, HIRSH et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. J. Am. Med. Assoc. (2004) 292(2):251-266.
6. CARR A, SAMARASK, BURTON S et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 12:F51-F58.
7. KAKUDA TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. (2000) 22(6):685-708.
8. JOHNSON VA, BRUN-VEZINET F, CLOTET B et al.: Update of the drug resistance mutations in HIV-1: 2004. Top. HIV Med. (2004) 12:119-124.
9. GARCIA-LERMA JG: Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. J. Antimicrob. Chemother. (2005) 56:265-269.
10. GALLANT JE, STASZEWSKI S, POZNIAK et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. J. Am. Med. Assoc. (2004) 292:191-201.
11. POZNIAK A, GALLANT J, STASZEWSKI S et al.: Long-term efficacy and safety of tenofovir DF (TDF): a 144-week comparison versus stavudine (d4T) in antiretroviral-naive patients. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004). Abstract PL6.3.
12. SAAG MS, CAHN P, RAFFI F et al.: Efficacy and safety of emtricitabine versus stavudine in combination therapy in antiretroviral-naive patients. A randomized trial. J. Am. Med. Assoc. (2004) 292:180-190.
13. ARRIBAS J, DEJESUS E, CAMPO R et al.: The combination of tenofovir DF (TDF), emtricitabine and efavirenz (EFV) has significantly greater response versus fixed dose zidovudine/lamivudine (combivir) and EFV in antiretroviral naive patients: a 48 weeks preliminary analysis. 18th International Conferenca on Antiviral Research. Barcelona, Spain (2005). Abstract LB01.
14. DEEKS SG: International perspectives on antiretroviral resistance. Non-nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S25-S33.
15. CUNNINGHAM CK, CHAIX ML, REKACEWICZ C et al.: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials groups protocol 316. J. Infect. Dis. (2002) 186:181-188.
16. ESHLEMAN SH, JACKSON JB: Nevirapine resistance after a single dose prophylaxis. AIDS Rev. (2002) 4:59-63.
17. DE CLERCQ E: Emerging anti-HIV drugs. Expert Opin. Emerg. Drugs (2005) 10:241-274.
18. KIM EY, VRANG L, OBERG B, MERIGAN TC: Anti-HIV type-1 activity of 3′-fluoro-3′deoxythymidine for several different multidrug-resistam mutants. AIDS Res. Hum. Retroviruses (2001) 17:401-407.
19. COX SW, ALBERT J, LJUNGDAHL S, WAHREN B: Effect of resistance on combination chemotherapy for human immunodeficiency virus infection. Adv. Enzyme Regul. (1993) 33:27-36.
20. VRANG L, ZHANG H, PALMER S et al.: In vitro effects of MIV-310 (alovudine, 3′-fluorodeoxythymidine, FLT) against HIV mutants. Antivir. Ther. (2002) 7:2.
21. KONG XB, ZHU QY, VIDAL PM et al.: Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxy thymidine and 3′-azido-3′deoxythymidine. Antimicrob. Agents Chemother. (1992) 36:808-818.
22. LJUNGDAHL S, GUZENDA E, BOTTIGER D et al.: Penetration of zidovudine and 3′-fluoro-3′-deoxythymidine into brain, muscle tissue and veins in cynomolgus monkeys: relation to antiviral action. Antimicrob. Agents Chemother. (1992) 36:2418-2422.
23. FLEXNER C, VAN DER HORST C, JACOBSOM MA et al.: Relashinship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-control trials. J. Infect. Dis. (1994) 170:1394-1403.
24. KATLAMA C, GHOSN J, TUBIANA R et al.: MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week Phase II study. AIDS (2004) 18:1299-1304.
25. GU Z, WAINBERG MA, HGUYEN BA N et al.: Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. (1999) 43:2376-2382.
26. FURMAN PA, JEFFREY J, KIEFER LL et al.: Mechanism of action of 1-β-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolane guanosine. Antimicrob. Agents Chemother. (2001) 45:158-165.
27. MEWSHAW JP, MYRICK FT, WAKEFIELD et al.: Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. (2002) 29:11-20.
28. CHEN H, SCHINAZI RF, RAJAGOPALAM P et al.: Pharmacokinetics of (-)-β-D-dioxolane guanine and prodrug (-)-β-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Hum. Retroviruses (1999) 15:1625-1630.
29. KESSLER H, ERON J, THOMPSON M et al.: Anti-HIV activity and tolerability of DAPD, a novel dioxolane guanine RT inhibitor: preliminary results of a Phase I/II clinical trial. 13th International Conference on AIDS. Durban, South Africa (2000). Abstract 3198.
30. THOMPSON M, RICHMOND G, KESSLER H et al.: Preliminary results of dosing of amdoxovir in treatment-experienced patients. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003). Abstract 554.
31. GRIPSHOVER B, SANTANA J, RIBAUDO H et al.: A randomized, placebo-controlled trial of amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-infected subjects failing current therapy (AACTG 5118). 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 553.
32. SHI J, MCATEE JJ, WIRTZ SS et al.: Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytid ine (D4FC) analogues: discovery of carboxylic nucleosides triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. (1999) 42:859-867.
33. GELEZIUNAS R, GALLAGHER K, ZHANG H et al.: HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor, β-D-2′3′- dideoxy-2′,3′-didehydro-5-flourocytidine. Antivir. Chem. Chemother. (2003) 14:49-59.
34. ERIKSON-VITANEN S, WU J-T, SHI G et al.: Cellular pharmacology of D-D4FC, a nucleoside analog active against drug-resistant HIV. Antivir. Chem. Chemother. (2003) 14:39-47.
35. SCHINAZI RF, MELLORS J, BAZMI H et al.: DPC-817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Atimicrob. Agents Chemother. (2002) 46:1394-1401.
36. MURPHY RL, SCHURMANN D, BEARD A et al.: Tolerance and potent anti-HIV-1 activity of reverset following 10 days of monotherapy in treatment-naive individuals. 11th Conference on Retroviruses and Opportunistic Infections, San Fransisco, USA (2004). Abstract 137.
37. MURPHY RL, SCHURMANN D, BEARD A et al.: Potent anti-HIV-1 activity of reverset following 10 days of monotherapy in treatment-naive individuals. 15th International Conference on AIDS. Bangkok, Thailand (2004). Abstract MoOr1056.
38. MURPHY RL, SCHURMANN D, LEVY R et al.: Tolerance and activity of reverset following 10 days as add-on therapy to current regimens in treatment experienced HPV-1 infected individuals. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004). Abstract H-1130.
39. LOCAS C, CHING S, DAMMENT S: Safety profile of SPD754 in cynologus monkeys treated for 52 weeks, 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, USA (2004). Abstract 527.
40. DE MUYS JM, GOURDEAU H, NGUYEN BN et al.: Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob. Agents Chemother. (1999) 43(8):1835-1844.
41. BETHELL R, COLLINS P, HOLDICH T, SAWYER J: In vitro and in vivo antiviral activity of SPD-754 against wild-type and NRTI-resistant viruses. 15th International Conference on AIDS. Bangkok, Thailand (2004). Abstract WePeA5642.
42. TAYLOR DL, AHMED PS, TYMS AS et al.: Drug resistance and drug combination features of the human immunodefidiency virus inhibitor, BCH-10652 [(+/-)-2′-oxa-4′-thiocytidine, dOTC]. Antivir. Chem. Chemother. (2000) 11(4):291-301.
43. RICHARD N, SALOMON H, RANDO R et al.: Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′thio-5-fluorocytidine. Antimicrob. Agents Chemother. (2000) 44(5):1127-1131.
44. GU Z, NGUYEN-BA N, MELLORS J, FORTIER C, WAINBERG M: In vitro selection and characterization of HIV-1 resistance to BCH-10618. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001). Abstract 472.
45. ADAMS J, SAWYER J, SHIVERLY L: Intracellular SPD754 triphosphate pharmacokinetics following administration od SPD754 capsules. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). Abstract 599.
46. FORREST A, SMITH P, SAWYER J, FOX L, SHIVELEY: Single dose pharmacokinetics of SPD 754 in healthy adult volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (2002). Abstract A1406.
47. SMITH PF, FORREST A, ADAMS JM, BALLOW CH: Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate. J. Clin. Pharmacol. (2002) 42(6):658-661.
48. BETHELL R, ADAMS, DE MUYS J et al. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). Abstract 138.
49. CAHN P, LANGE J, CASSETTI I et al.: Anti-HIV-1 activity of SPD-754 a new NRTI: results of a 10 day monotherapy study in treatment naive HIV patients. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France (2003). Abstract LB15.
50. CAHN P, VAN LEEUWEN R, SAWYER J, SHIVELEY L: Tolerability and anti-HIV-1 activity of SPD-754 in 10 days monotherapy in treatment naive patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2003). Abstract H-869.
51. COLLINS P, SHIVELEY L, ANDERSON C, BETHELL R: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD-754. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). Abstract 526.
52. BETHELL RC, COLLINS P: Genotypic and phenotypic analysis of HIV-1 isolates from patients after 10 days of monotherapy with SPD-754. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004). Abstract H-207.
53. Bethell RC, DE ROOJ ER, SMOLDERS GM et al.: Comparison of In vitro mitochondrial toxicity of SPD-754 in HepG2 cells with nine other nucleoside reverse transcriptase inhibitors. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004). Abstract H-206.
54. CHEN S, LIN S, KING I et al.: Synthesis and comparative evaluation of two antiviral agents: β-L-FD4C and β-D-FD4C. Bioorg. Med. Chem. Lett. (1998) 8:3245-3250.
55. DUNKLE LM, OSHANA S, DICKINSON J, CHENG Y, RICE WG: Safety and pharmacokinetics of ACH 126,443, a potent anti-HIV and HBV nucleoside. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2001).
56. DUNKLE LM, GATHE JC, PEDEVILLANO DE et al.: Elvucitabine: potent antiviral activity demonstrated in multi-drug resistant HIV infection. Antivir. Ther. (2003)8:256-261.
57. BLACK PL, USSERY MA, OTTO MJ et al.: Potent antiviral activity of racivir in the HuPBMC-SCID mouse model of HIV infection. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART. San Juan, Puerto Rico (2000).
58. OTTO MJ, ARASTEH K, SCHULBIN H et al.: Single and multiple dose pharmacokinetics and safety of the nucleoside racivir in male volunteers. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART. Naples, USA (2002).
59. HAZERMANN C, ARASTEH K, MURPHY RL et al.: Safety, Pharmacokinetics, and efficacy of (+/-)-2′,3′-dideoxy-5-fluoro-3′-thiacytidine with efavirnez and stavudinein antiretroviral-naïve human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2005) 49:2828-2833.
60. CHU CK, YADAV V, RAPP K, CHONG Y, SCHINAZI R: Dioxolane thymidine nucleoside is active against a variety of NRTI-resistant mutants. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 554
61. CHU CK, YADAV V, CHONG YH, SCHINAZI RF: Anti-HIV activity of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxol an-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J. Med. Chem. (2005) 48:3949-3952.
62. SCHINAZI RF, ASIF G, DETORIO M et al.: 1-(β-D-dioxolane)thymine (DOT) is a TK-dependent orally bioavailable nucleoside with specific activity against HIV-1 resistant variants. 14th International HIV Drug Resistance Workshop. Quebec City, Canada (2005). Abstract 58.
63. KODAMA EI, KOHGO S, KITANO K et al.: 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother. (2001) 45:1539-1546.
64. KUMAMOTO H, HARAGUCHI K, TANAKA H et al.: Synthesis of (+/-)-ethynyl and 4′-cyano carbocyclic analogues of stavudine (d4T). Nucleosides Nucleotides Nucleic Acids (2005) 24:73-83.
65. HARAGUCH K, TAKEDA S, SUDINO M et al.: A new approach to the synthesis of 4′-carbon-substituted nucleosides: development of a highly active anti-HIV agent 2′, 3′ didehydro-3′-deoxy-4′- ethynylthymidine. Nucleosides Nucleotides Nucleic Acids (2005) 24:343-347.
66. UCKUN FM, PENDERGRASS S, QAZI S, VENKATACHALAM TK: In vitro activity of stampidine against primary clinical immunodeficiency virus isolates. Arzneimittelforshung (2004) 54:69-77.
67. UCKUN FM, QAZI S, VENKATACHALAM TK: In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforshung (2004) 55:223-231.
68. UCKUN FM, CHEN CL, LISOWSKI E et al.: Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforshung (2003) 53:357-367.
69. FUJIWARA T, SATO A, EL-FARRASH M et al.: S-1153 inhibits replication of known drug-resistant strains of HIV-1. Antimicrob. Agents Chemother. (1998) 42:1340-1345.
70. REN J, NOCHOLS C, BIRD LE et al.: Binding of the second generation non-nucleoside inhibitors S-1153 to HIV-1 reverse transcriptase involves extensive chain hydrogen bonding. J. Biol. Chem. (2000) 275:14316-14320.
71. WOLFE P, HAWLEY P, BOCCIA G et al.: Safety and efficacy of capravirine versus placebo in HIV-infected patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen: results of a Phase II, double-blind, placebo-controlled study. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001). Abstract 323.
72. PESANO R, PIRAINO S, HAWLEY P et al.: 24 and 48 week safety, tolerability, and efficacy of capravirine (CPV) as add-on therapy to nelfinavir and 2 nucleoside reverse transcriptase inhibitors (NRTIs) in patients failing a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 555.
73. DE CORTE: From 4,5,6,7-tetrahydro-5-methylimidazol[4,5,1-jk] (1,4) benzodiazepin-2 (1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. (2005) 48:1689-1696.
74. LUDOVICI D, DE CORTE BL, KUKIA MJ et al.: Evolution of anti-HIV drugs candidates.3. Diarylpyrimidines analogues. Bioorg. Med. Chem. Lett. (2001) 11:2235-2239.
75. GRUZDEV B, HORBAN A, BORON-KACZMARSKAA, GILLE D, VAN'T KLOOSTER G, PAUWELS R: TMC-120, a new non- nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment-naive, HIV-1-infected subjects. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001). Abstract 13.
76. VAN HERREWEGE Y, MICHIELS J, VAN ROEY J et al.: In vitro evaluation of nonucleoside reverse transcriptae inhibitors UC-781 and TMC-120-R147681 as human immunodeficiency virus microbicide. Antimicrob. Agents Chemother. (2004) 48:337-339.
77. DAS K, CLARK AD Jr, LEWI PJ et al.: Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. (2004) 47:2550-2560.
78. ANDRIES K, AZIJN H, THIELEMANS T et al.: TMC-125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2004) 48:4680-4686.
79. GAZZARD BG, POZNIAK AL, ROSENBAUM W et al.: An open-label assessment of TMC-125 - a new next-generation NNRTI for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS (2003) 17:49-54.
80. SANKATSING SU, WEVERLING GJ, PEETERS M et al.: TMC-125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS (2003) 17:2623-2627.
81. DE BETHUNE MP, ANDRIES K, AZIJN H et al.: TMC-278, a new potent NNRTI with an increased barrier to resistance and favourable pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 556.
82. GOEBEL F, YAKOVLEV A, POZNIAK A et al.: TMC-278 potent anti-HIV activity in antiretroviral naive patients. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 160.
83. BONNEAU P, ROBINSON P, DUAN J et al.: Antiviral characterization and human experience with BILR-355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor with a broad anti HIV-1 profile. 12th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2005). Abstract 558.
84. BONNEAU P, ROBINSON PA, LYE Y, VAN LEEUWEN R, BETHELL R: Antiviral profile of BILR-355 BS against a large panel of clinical isolates with mutations conferring resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTI). 14th HIV Drug resistance Workshop. Quebec City, Canada (2005). Abstract 74.
85. ROBERTS G, PORTER D, BOONE L et al.: Kinetic and thermodynamic parameters for binding of the non-nucleoside inhibitors GW-678248 and GW-695634 to wild type and 12 mutants of HIV1-reverse transcriptase. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). Abstract 529.
86. KIM Y, SYMONDS W, STEEL H et al.: Safety and pharmacokinetics of 695634 following repeat oral dose administration to healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, USA (2004). Abstract A-23.
87. AUWERX J, RODRIGUEZ-BARRIOS F, CECCHERINI-SILBERSTEIN F et al.: The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. Mol. Pharmacol (2005) 68:652-659.
88. QUAN Y, MOTAKIS D, BUCKHEIT R Jr et al.: Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antivir. Ther. (1999) 4:203-209.
89. CREAGH T RUCKLE JL, TOLBERT DT et al.: Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob. Agents Chemother. (2001) 45:1379-1386.
90. SHERER R, DUTTA B, ANDERSON R et al.: A Phase IB study of (+)-calanolide A in HIV-1-infected, antiretroviral-therapy-naive patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2000). Abstract 508.
91. KLUMPP K, HANG JQ, RAJENDRAN S et al.: Two-metal ion mechanism of RNA cleavage by HIV Rnase H and mechanism-based design of selective HIV Rnase H inhibitors. Nucleic Acids Res. (2003) 31:6852-6859.
92. TRAMONTANO E, ESPOSITO F, BADAS R et al.: 6-[1-(4-Fluorophenyl)methyl-1H- pyrrol-2-yl]-2,4-dioxo-5-hexenoic acid ethyl esther a novel diketo acid derivative which selectively inhibits the HIV-1 replication in cell culture and the ribonuclease H activity in vitro. Antivir Res. (2005) 65:117-124.
93. BUDIHAS SR, CORSHKOVAI, GAIDAMAKOV S et al.: Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acid Res. (2005) 33:1249-1256.